FOLD News and Press, Amicus Therapeutics Inc. From 10/01/19

CRANBURY, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences: An oral presentation highlighting Phase 1/2 results, including coho...

Shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) shed 20% of their value in August, according to data from  S&P Global Market Intelligence . And what caused investors to head for the exits last month? Apparently, a question. On Aug. 8, Amicus released its se...

CRANBURY, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell, President and Chief Operating Officer, and Jeff Castelli, Chief Portfolio Officer and Head o...

Amicus Therapeutics ( FOLD ) had achieved positive Interim results using its gene therapy to treat patients with Batten disease. This proves that the biotech's gene therapy was able to halt the progression of the disease and offer the ability to improve motor and language functions in pati...

Amicus Therapeutics, Inc. (FOLD) Q2 2019 Results Earnings Conference Call August 8, 2019, 08:00 AM ET Company Participants Sara Pellegrino - Vice President of Investor Relations and Corporate Communication John Crowley - Chairman and Chief Executive Officer Bradley Campbell - Pre...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Amicus Therapeutics (NASDAQ: FOLD ): Q2 GAAP EPS of -$0.36 misses by $0.03 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

            2Q19 Galafold ® (migalastat) Revenue of $44.1M Represents Highest Quarterly  Growth Since Launch Driven by Continued Strong Global Uptake  Reiterating FY19 Revenue Guidance of $160M-$180M Fu...

          First Oral Precision Medicine Approved for People Living with Fabry Disease with an Amenable Mutation in Argentina First Amicus Regulatory Approval in Latin America CRANBURY, N.J., and BUENOS AIRES, Argentina, Aug. 02, 2019 (GLOBE NEWSWIRE) -- A...

Amicus Therapeutics (NASDAQ: FOLD ) perks up  2%  premarket on light volume in response to encouraging preliminary data from a Phase 1/2 clinical trial evaluating its AAV-CLN6 gene therapy in patients with a rare inherited nervous system disorder called CLN6 Batten disease . M...